A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis

201293 citationsJournal Articlebronze Open Access

Authors

Craig B. Langman · Northwestern University

Larry A. Greenbaum · Emory University

Minnie Sarwal · Stanford Medicine

Paul C. Grimm · Stanford University

Patrick Niaudet · Hôpital Necker-Enfants Malades

Georges Deschênes · Hôpital Robert-Debré

Elisabeth A. M. Cornelissen ·

Abstract

A new delayed-release Q12H formulation of cysteamine bitartrate is not inferior to the Q6H formulation (Cystagon) in maintaining low WBC cystine levels in patients with cystinosis but at a lower total daily dose.

Topics & Keywords

Biomedical Research and Pathophysiology Neonatal Health and Biochemistry Methemoglobinemia and Tumor Lysis Syndrome

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Journal of the American Society of Nephrology

Volume 7, Issue 7, pp. 1112-1120

DOI: 10.2215/cjn.12321211

Field-Weighted Citation Impact: 5.33